A LinkedIn post from Glooko highlights upcoming clinical data to be presented at the 2026 American Association of Clinical Endocrinology Annual Meeting in Las Vegas. The post notes that Glooko’s Paul Chidester, M.D., and Advocate Health Wake Forest Baptist Hospital’s Joe Aloi, M.D., will present results on the EndoTool Glucose Management System, developed by Monarch Medical Technologies.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to the post, the data describe how EndoTool is being used to transform inpatient diabetes and glycemic care across a 19-hospital health system in North Carolina. For investors, the focus on system-wide inpatient deployment suggests potential for broader health-system adoption, which could support recurring software and services revenue streams if outcomes and safety benefits are validated.
The collaboration with a large health system and presence at a major endocrinology meeting may enhance the visibility and clinical credibility of Glooko’s and Monarch’s solutions among hospital decision-makers. If the clinical results demonstrate meaningful improvements in glycemic safety and operational efficiency, this could strengthen the companies’ competitive positioning in the growing market for digital and algorithm-driven inpatient glucose management.